Mafodotin
Blenrep (mafodotin) is a small molecule pharmaceutical. Mafodotin was first approved as Blenrep on 2020-08-25. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blenrep | Biologic Licensing Application | 2025-10-23 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg |
Clinical
Clinical Trials
86 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 39 | 42 | 10 | — | 7 | 71 |
| Plasma cell neoplasms | D054219 | — | — | 16 | 14 | 1 | — | 5 | 24 |
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | 2 | 2 | — | — | 6 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | 1 | — | — | 2 |
| Gliosarcoma | D018316 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 4 | 5 | — | — | — | 6 |
| Neoplasms | D009369 | — | C80 | 4 | 5 | — | — | — | 5 |
| Corneal diseases | D003316 | — | H18.9 | 3 | 3 | — | — | 1 | 4 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 1 | 3 | — | — | — | 3 |
| Follicular lymphoma | D008224 | — | C82 | 1 | 3 | — | — | — | 3 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 3 | 3 | — | — | — | 3 |
| Blood protein disorders | D001796 | — | — | 3 | 3 | — | — | — | 3 |
| Paraproteinemias | D010265 | — | D47.2 | 3 | 3 | — | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | — | — | — | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 2 | — | — | — | 2 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
| Agranulocytosis | D000380 | HP_0012234 | D70 | — | — | — | — | 1 | 1 |
| Opportunistic infections | D009894 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mafodotin |
| INN | belantamab mafodotin |
| Description | Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of the approved drug belantamab mafodotin in multiple myeloma and some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody.
|
| Classification | Small molecule |
| Drug class | synthetic analogs of the dolastatin series |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 745017-94-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107813 |
| ChEBI ID | — |
| PubChem CID | 10395173 |
| DrugBank | — |
| UNII ID | DB1041CXDG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TNFRSF17
TNFRSF17
Organism
Homo sapiens
Gene name
TNFRSF17
Gene synonyms
BCM, BCMA
NCBI Gene ID
Protein name
tumor necrosis factor receptor superfamily member 17
Protein synonyms
B cell maturation antigen, B-cell maturation factor, B-cell maturation protein, CD269
Uniprot ID
Mouse ortholog
Tnfrsf17 (21935)
tumor necrosis factor receptor superfamily member 17 (O88472)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,987 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blenrep
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,803 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use